NCT05498220 2026-04-16Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell LymphomaUNC Lineberger Comprehensive Cancer CenterPhase 2 Terminated5 enrolled 13 charts